IDAMYCIN PFS Drug Patent Profile
✉ Email this page to a colleague
When do Idamycin Pfs patents expire, and what generic alternatives are available?
Idamycin Pfs is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in IDAMYCIN PFS is idarubicin hydrochloride. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the idarubicin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Idamycin Pfs
A generic version of IDAMYCIN PFS was approved as idarubicin hydrochloride by PFIZER on February 17th, 1997.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for IDAMYCIN PFS?
- What are the global sales for IDAMYCIN PFS?
- What is Average Wholesale Price for IDAMYCIN PFS?
Summary for IDAMYCIN PFS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 67 |
| Clinical Trials: | 31 |
| Patent Applications: | 7,767 |
| Drug Prices: | Drug price information for IDAMYCIN PFS |
| What excipients (inactive ingredients) are in IDAMYCIN PFS? | IDAMYCIN PFS excipients list |
| DailyMed Link: | IDAMYCIN PFS at DailyMed |
Recent Clinical Trials for IDAMYCIN PFS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Jiangxi Province Children's Hospital | Phase 2/Phase 3 |
| The First Affiliated Hospital of Nanchang University | Phase 2/Phase 3 |
| Second Xiangya Hospital of Central South University | Phase 2/Phase 3 |
Pharmacology for IDAMYCIN PFS
| Drug Class | Anthracycline Topoisomerase Inhibitor |
| Mechanism of Action | Topoisomerase Inhibitors |
US Patents and Regulatory Information for IDAMYCIN PFS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | IDAMYCIN PFS | idarubicin hydrochloride | SOLUTION;INTRAVENOUS | 050734-001 | Feb 17, 1997 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
